Article Per Year (5 Year)
p-Index From 2021 - 2026
1.704
P-Index
This Author published in this journals
All Journal Jurnal Ilmu Kedokteran (Journal of Medical Science) Pharmaciana: Jurnal Kefarmasian Jurnal Kesehatan Melayu Jurnal Gizi Klinik Indonesia JURNAL FARMASIMED (JFM) Jurnal Riset Kesehatan Poltekkes Depkes Bandung Jurnal Respirasi (JR) Narra J Jurnal Ilmiah Kesehatan (JIKA) Indonesian Journal of Cancer Jurnal Kesehatan
Darmawi Darmawi
Fakultas Kedokteran Universitas Riau
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 13 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 13 Documents
Search

 1   2 
Gastrointestinal Adverse Effects of Elobixibat in Chronic Constipation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Citra Safitri Wirman; Rudi Erwin Kurniawan; Darmawi; Benni Iskandar
Jurnal FARMASIMED (JFM) Vol 8 No 2 (2026): Jurnal Farmasimed (JFM)
Publisher : Fakultas Farmasi Institut Kesehatan Medistra Lubuk Pakam

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35451/3rncke15

Abstract

Chronic constipation is a common gastrointestinal disorder that negatively affects quality of life and increases healthcare burden worldwide. Elobixibat, an ileal bile acid transporter inhibitor, has been introduced as a novel therapy to enhance intestinal fluid secretion and improve colonic motility in patients with chronic constipation. However, concerns remain regarding gastrointestinal adverse effects, particularly their potential relationship with dosage. Therefore, this study aimed to evaluate gastrointestinal adverse effects associated with elobixibat and to assess whether these events demonstrate a dose-dependent pattern. This systematic review and meta-analysis followed the PRISMA 2020 guidelines and was registered in PROSPERO (CRD420251155537). A literature search was conducted in PubMed and ScienceDirect to identify randomized controlled trials investigating elobixibat in chronic constipation patients published up to December 2025. Study eligibility was determined using the PICOS framework. Data on adverse effects, dosage, and treatment duration were extracted and analyzed using proportional meta-analysis with a random-effects model in R Studio, and risk of bias was assessed using the RoB2 tool. Five randomized controlled trials involving 922 participants are included in the analysis. The pooled proportion of diarrhea is 21%, abdominal distension is 26%, and abdominal pain is 16%, while unspecified gastrointestinal disorders represent the most frequently reported adverse events at 49%. Overall, gastrointestinal adverse events show a dose-dependent pattern, with higher doses associated with increased event rates. These findings indicate that elobixibat is associated with dose-dependent gastrointestinal adverse effects, highlighting the importance of individualized dosing and gradual titration to improve treatment tolerability.
Therapeutic Potential of Topical Metformin in Diabetic Wound Healing: Preclinical Mechanistic Insights Citra Safitri Wirman; Darmawi; Benni Iskandar
Jurnal Kesehatan - STIKes Prima Nusantara Vol 17 No 2 (2026): Jurnal Kesehatan (on progress)
Publisher : LPPM Universitas Prima Nusantara Bukittinggi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35730/jk.v17i2.1657

Abstract

Diabetic wounds remain one of the most challenging complications of diabetes mellitus, largely due to persistent inflammation, oxidative stress and impaired tissue regeneration. These conditions contribute to delayed healing and increase the risk of infection and amputation. In recent years, topical metformin has gained attention as a potential therapeutic option to improve wound healing outcomes. This review aims to summarize current preclinical evidence on the effectiveness of topical metformin, with a particular focus on its underlying molecular mechanisms. Evidence from experimental studies suggests that topical metformin can accelerate wound healing through several interconnected pathways, including activation of AMP-activated protein kinase (AMPK), suppression of NF-κB–mediated inflammation, reduction of reactive oxygen species (ROS) and regulation of extracellular matrix remodeling. Moreover, the advancement of sophisticated delivery technologies, such as hydrogels and nanocomposites has significantly augmented the localized therapeutic efficacy of metformin. The evidence suggests that topical metformin may be a new way to treat diabetic wounds. However, additional rigorously planned studies and clinical trials are necessary to validate its safety, enhance its formulation and facilitate its clinical use. Keywords : AMPK activation; Diabetic wound; Inflammation; Preclinical evidence; Topical metformin
Downregulation of RGS2 Expression in Ovarian Cancer: A TCGA–GTEx Transcriptomic Analysis Annisa Abdi Ghifari; Marni Sianturi; Suyanto Suyanto; Zahtamal Zahtamal; Darmawi Darmawi
Jurnal Ilmiah Kesehatan (JIKA) Vol. 8 No. 2 (2026): Volume 8 Nomor 2 Agustus 2026
Publisher : Sarana Ilmu Indonesia (Salnesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36590/jika.v8i2.1604

Abstract

Regulator of G protein signaling 2 (RGS2), a negative regulator of G protein-coupled receptor signaling, is implicated in ovarian cancer. Given the disease's late-stage diagnosis and poor prognosis, identifying reliable molecular biomarkers is crucial. This study evaluated RGS2 gene expression in ovarian cancer and its clinicopathological and prognostic associations using public transcriptomic data. RNA-sequencing data from 419 The Cancer Genome Atlas (TCGA) tumor samples and 88 Genotype-Tissue Expression (GTEx) normal samples were compared using the Mann-Whitney U test. Additionally, 308 TCGA cases were analyzed for associations with tumor grade, clinical stage, and survival outcomes—including overall survival (OS), disease-specific survival (DSS), progression-free interval (PFI), and disease-free interval (DFI) using the Kaplan-Meier method and log-rank tests based on median RGS2 expression. Results demonstrated that RGS2 was significantly down-regulated in ovarian cancer tissues compared to normal tissues (p<0,001). However, RGS2 expression showed no significant correlation with tumor grade, clinical stage, or any evaluated survival metrics (all p>0,05). In conclusion, while RGS2 is consistently down-regulated at the transcript level in ovarian cancer, it is not significantly associated with patient survival. These findings suggest that although reduced RGS2 expression is a common molecular feature of ovarian cancer, its utility as a standalone prognostic biomarker is limited in unstratified transcriptomic analyses.
Co-Authors Afdal Afdal, Afdal Afief, Arief R. Annisa Abdi Ghifari Arfianti Arfianti Auren Nathania Benni Iskandar BENNI ISKANDAR Citra Safitri Wirman Citra Safitri Wirman Dani Rosdiana Donel S Dwiputri, Rinesia Elva Rosiana Fifia Chandra Hamidy, Muhammad Y. Huriatul Masdar Indi Esha Indra Yovi Irham, Lalu M. Kemal, Rahmat A. Lalu Muhammad Irham Leina Putri Zahra Marni Sianturi Maya Savira Muhammad Khairani Muhammad Yusuf Nurfi Pratiwi, Nurfi Ocktariyana, Ocktariyana Pangaribuan, Machyuddin Tumpak Marojahan Pragita Ayu Saputri Rachmadina, Rachmadina Rangkuti, Ina F. Razali, Renardy Reza Renardy Reza Razali Rudi Erwin Kurniawan Soraya Soraya Sri Melati Munir Suyanto Suyanto Tiara Fani, Rifia Ulfah, Aida J. Winarto Winarto Winarto Winarto Wirawan Adikusuma Wiwin Suhandri Wiwit Ade Fidiawati Zahlina, Dian Zahtamal Zahtamal Zahtamal Zahtamal Zarfiardy Aksa Fauzi